APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer
about
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.In Favor of Establishment: Regulation of Chromatid Cohesion in PlantsGlioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibitionMulti-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel BiomarkersThe β-isoform of BCCIP promotes ADP release from the RAD51 presynaptic filament and enhances homologous DNA pairing.Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1.The landscape of microsatellite instability in colorectal and endometrial cancer genomes.Functional assays for analysis of variants of uncertain significance in BRCA2.Diverse developmental disorders from the one ring: distinct molecular pathways underlie the cohesinopathies.Therapeutic opportunities within the DNA damage response.BAF180 promotes cohesion and prevents genome instability and aneuploidy.Cohesin mutations in human cancerOverexpression of APRIN inhibits differentiation and proliferation and promotes apoptosis in P19 embryonal carcinoma cells.Brca2, Pds5 and Wapl differentially control cohesin chromosome association and function.
P2860
4ba0c7ddceafcbf02aa3df1cb5429415e48e540f5184424022a2e759952ac6187a480a09699cd323812e2aa340bd1f9ce7b2e32deddf95f231db5559a033a4264f295727f26e321a09a732ff4f927c5caf927804587d8c9959469910bd59bc3ce05338fbb12f5d6150afebc496e6f1a5525458e811443c5bbf03b137cf8719ca26d80d821cf07d7e06cbfe0ee0e598e051562ddc033bcd39fb14c0d0513ca727
P248
Q27852678-20CE2FE6-731D-40E6-BD60-7F9700C36D4AQ33716096-C9C012C2-E391-465D-8214-FB664E982C76Q34034221-151293D8-8427-4545-86ED-1B50E523173EQ35871650-574AC1CF-81F4-41BF-BB0A-5674B2485EEEQ36150755-0E4AFDC5-FB43-428C-A6B0-828A462B354DQ36214613-32C28C7A-F148-4865-BADC-27DD2B8A3768Q37323033-505AF76B-6E01-4EC3-9211-2BDABBF3B3CCQ37412188-E4F6F590-7D55-46AE-8D86-038927BFA62EQ37715826-3C7B7D6B-2141-4B97-AFC4-A687A1436799Q38044384-CE550696-CF55-4A84-86FA-23F40CD49772Q38364665-855EAE53-1261-439A-A664-977F7DC41DD9Q38786462-069FC940-D36C-49FC-8307-52B92CF3564CQ38840393-86AC294D-DE7C-4026-BB4A-2DC28A122E8BQ39262202-079AA31F-0B53-43F0-94A3-E4A1CC60200BQ49980573-E64263CC-9C84-4623-9D45-124DA1A4FD65
P2860
APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@ast
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en-gb
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@nl
type
label
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@ast
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en-gb
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@nl
prefLabel
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@ast
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en-gb
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@nl
P2093
P2860
P50
P356
P1433
P1476
APRIN is a cell cycle specific ...... chemotherapy in breast cancer
@en
P2093
Ilirjana Bajrami
Rachel Brough
Radost Vatcheva
P2860
P304
P356
10.1038/EMBOJ.2011.490
P407
P577
2012-03-07T00:00:00Z